Ahmed Arif Medical Research Center

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).	Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus	Recruiting	Phase 3	2026-10-01	NCT06133972
Secukinumab Open Label Roll-over Extension Protocol	Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, immune system disorder	Recruiting	Phase 4	2026-09-28	NCT04638647
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)	Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus	Active, not recruiting	Phase 3	2026-08-21	NCT05624749
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease	Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, systemic lupus erythematosus	Active, not recruiting	Phase 2	2026-06-05	NCT06293365

Clinical trials